论文部分内容阅读
Objective:Acute myeloid leukemia progressed from myelodysplastic syndrome(MDS/AML)is generally incurable with poor prognosis for complex karyotype including monosomy 7(-7).Qinghuang Powder(青黄散,QHP),which includes Qing Dai(Indigo naturalis)and Xiong Huang(realgar)in the formula,is effective in treating MDS or MDS/AML even with the unfavorable karyotype,and its therapeutic efficacy could be enhanced by increasing the Xiong huang content in the formula,while Xiong huang contains>90%arsenic disulfide(As_2S_2).F-36p cell line was established from a MDS/AML patient with complex karyotype including-7,and was in cytokine-dependent.The present study was to investigate the effects of AS_2S_2 on F-36p cells.Methods:Cell proliferation was measured by an3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT)assay.Cell apoptosis was identified by Annexin V-staining.Cell viability was determined by a propidium iodide(PI)exclusion.Erythroid differentiation was evaluated by the expression of cell surface antigen CD235a(GpA).Results:After treatment with AS_2S_2,at concentrations of 0.5to 16μmol/L for 72 h,As_2S_2 inhibited the proliferation of F-36p cells.The 50%inhibitory concentrations(IC_(50))of As_2S_2against the proliferation of F-36p cells was 6μmol/L.The apoptotic cells significantly increased in a dose-dependent mannar(P<0.05).The cell viabilities were significantly inhibited by As_2S_2 dose-dependent in a dose-dependent manner(P<0.05).Significant increases of CD235a-positive cells were concurrently observed(P<0.05)also in a dosedependent manner.Conclusions:As_2S_2 could inhibit proliferation and viability,induce apoptosis,and concurrently promote erythroid differentiation dose-dependently in F-36p cells.AS_2S_2 can inhibit proliferation and viability,induce apoptosis,and concurrently promote erythroid differentiation in cytokine-dependent MDS-progressed human leukemia cell line F-36p with complex karyotype including-7.The data suggest that QHP and/or As_2S_2 could be a potential candidate in the treatment of MDS or MDS/AML even with unfavorable cytogenetics.
Objective: Acute myeloid leukemia progressed from myelodysplastic syndrome (MDS / AML) is generally incurable with poor prognosis for complex karyotype including monosomy 7 (-7) .Qinghuang Powder (QHP), which includes Qing Dai (Indigo naturalis) and Xiong Huang (realgar) in the formula, is effective in treating MDS or MDS / AML even with the unfavorable karyotype, and its therapeutic efficacy could be enhanced by increasing the Xiong huang content in the formula, while Xiong huang contains> 90% arsenic disulfide (As_2S_2) .F-36p cell line was established from a MDS / AML patient with complex karyotype including-7, and was in cytokine-dependent. The present study was to investigate the effects of AS_2S_2 on F-36p cells. Methods: Cell proliferation was measured by an3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (MTT) assay. Cell apoptosis was identified by Annexin V-staining. Cell viability was determined by a propidium iodide exclusion.Erythroid differentiation was evaluated by the expressi After treatment with AS_2S_2, at concentrations of 0.5 to 16 μmol / L for 72 h, As_2S_2 inhibited the proliferation of F-36p cells.The 50% inhibitory concentrations (IC_ (50)) of As_2S_2against the proliferation of F-36p cells was 6μmol / L.The apoptotic cells significantly increased in a dose-dependent mannar (P <0.05). The cell viabilities were significantly inhibited by As_2S_2 dose-dependent in a dose- dependent manner (P <0.05) .Significant increases in CD235a-positive cells were concurrently observed (P <0.05) also in a dose dependent manner. Conclusions: As_2S_2 could inhibit proliferation and viability, induce apoptosis, and concurrently promote erythroid differentiation dose-dependently in F-36p cells .AS_2S_2 can inhibit proliferation and viability, induce apoptosis, and concurrently promote erythroid differentiation in cytokine-dependent MDS-progressed human leukemia cell line F-36p with complex karyotype including-7.The data suggest that QHP and / or As_2S_ 2 couldbe a potential candidate in the treatment of MDS or MDS / AML even with unfavorable cytogenetics.